Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 study

被引：0

作者：

Haranaka, Miwa ^{[1
]}

Momose, Atsushi ^{[2
]}

Nakayama, Yoshikazu ^{[2
]}

Saito, Yuki ^{[2
]}

Spiessens, Bart ^{[3
]}

Davies, Todd A. ^{[4
]}

van den Dobbelsteen, Germie ^{[5
]}

Poolman, Jan ^{[5
]}

Sarnecki, Michal ^{[6
]}

机构：

[1] SOUSEIKAI PS Clin, Fukuoka, Japan

[2] Janssen Pharmaceut KK, 5-2 Nishikanda,3 Chome,Chiyoda Ku, Tokyo, Japan

[3] Janssen Pharmaceut, Janssen Res & Dev, Infect Dis & Vaccines, Beerse, Belgium

[4] Janssen Res & Dev, Raritan, NJ USA

[5] Janssen Vaccines & Prevent BV, Bacterial Vaccines Discovery & Early Dev, Leiden, Netherlands

[6] Janssen Vaccines, Janssen Res & Dev, Infect Dis & Vaccines, Bern, Switzerland

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2025年 / 31卷 / 01期

关键词：

ExPEC10V; Safety; Reactogenicity; Immunogenicity; Japanese population; INFECTION;

D O I：

10.1016/j.jiac.2024.09.003

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Aim: This phase 1 study (NCT04306302) evaluated the safety, reactogenicity, and immunogenicity of ExPEC10V (VAC52416) in healthy Japanese adults. Method: The randomized, double-blind, single-center study included 28-day screening, vaccination (Day 1), 30day safety and immunogenicity follow-up and 181-day serious adverse events (SAEs) follow-up. Participants (60-85 years) were enrolled in dose-ascending approach and randomized to medium- and high-doses of ExPEC10V (n = 8 in each dose group) and placebo (n = 8). Incidence of adverse events: solicited AEs (until Day 15), unsolicited AEs (until Day 30), SAEs (until Day 181) and immunogenicity (electrochemiluminescent-based assay [ECL] and multiplex opsonophagocytic assay [MOPA]) were assessed on Day 15 and Day 30. Results: Total of 24 participants were included (median age, 66.5 years; 50.0 % female). Incidence of solicited AEs was 81.3 % (local) and 18.8 % (systemic) for pooled ExPEC10V group (medium-dose ExPEC10V: 75.0 % [local], 12.5 % [systemic]; high-dose ExPEC10V: 87.5 % [local], 25.0 % [systemic]). One SAE, not vaccinerelated, was reported in high-dose ExPEC10V group after Day 30, which was resolved during study. The ECL demonstrated increase in binding antibody titers, which was maintained from Day 15 to Day 30. For all serotypes, the geometric mean fold increases from baseline on Day 15 ranged from 2.51 to 10.60 and 1.97-5.23 for medium- and high-dose groups, respectively. The MOPA demonstrated increase in functional antibody responses for all serotypes (except O8) at Day 15 which was maintained from Day 15 to Day 30. Conclusions: ExPEC10V medium- and high-doses were well tolerated with an acceptable safety profile without any significant safety issues in healthy Japanese participants.

引用

页数：8

共 28 条

[1] Poolman J.T., Wacker M., Extraintestinal pathogenic escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field, J Infect Dis, 213, pp. 6-13, (2016)
[2] Dale A.P., Woodford N., Extra-intestinal pathogenic escherichia coli (expec): disease, carriage and clones, J Infect, 71, pp. 615-626, (2015)
[3] Russo T.A., Johnson J.R., Medical and economic impact of extraintestinal infections due to escherichia coli: focus on an increasingly important endemic problem, Microb Infect, 5, pp. 449-456, (2003)
[4] Vila J., Saez-Lopez E., Johnson J.R., Romling U., Dobrindt U., Canton R., Et al., Escherichia coli: an old friend with new tidings, FEMS Microbiol Rev, 40, pp. 437-463, (2016)
[5] Geurtsen J., de Been M., Weerdenburg E., Zomer A., McNally A., Poolman J., Genomics and pathotypes of the many faces of escherichia coli, FEMS Microbiol Rev, 46, (2022)
[6] Bonten M., Johnson J.R., van den Biggelaar A.H.J., Georgalis L., Geurtsen J., de Palacios P.I., Et al., Epidemiology of escherichia coli bacteremia: a systematic literature review, Clin Infect Dis, 72, pp. 1211-1219, (2021)
[7] Sogaard M., Norgaard M., Dethlefsen C., Schonheyder H.C., Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study, Clin Infect Dis, 52, pp. 61-69, (2011)
[8] Fay K., Sapiano M.R.P., Gokhale R., Dantes R., Thompson N., Katz D.E., Et al., Assessment of health care exposures and outcomes in adult patients with sepsis and septic shock, JAMA Netw Open, 3, (2020)
[9] Rhee C., Kadri S.S., Dekker J.P., Danner R.L., Chen H.C., Fram D., Et al., Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use, JAMA Netw Open, 3, (2020)
[10] Ohmagari N., Choi W.S., Tang H.J., Atanasov P., Jiang X., Hernandez Pastor L., Et al., Targeted literature review of the burden of extraintestinal pathogenic escherichia coli among elderly patients in asia pacific regions, J Med Econ, 26, pp. 168-178, (2023)

← 1 2 3 →